Microchip battles retinitis pigmentosa

Article

Optobionics Corporation has announced positive interim results from a pilot clinical trial of its Artificial Silicon Retina (ASR) device, a treatment for retinitis pigmentosa.

Optobionics Corporation has announced positive interim results from a pilot clinical trial of its Artificial Silicon Retina (ASR) device, a treatment for retinitis pigmentosa.

A total of 20 patients were enrolled in a study to assess safety and to develop effective vision measures under an Investigational Device Exemption application approved by the FDA. At twelve months follow-up, of the ten subjects suffering with retinitits pigementosa, 40% attained a ten-letter improvement in visual acuity compared with a loss of vision for the untreated patients. No patient showed signs of implant rejection, infection, inflammation, erosion or retinal detachment related to the implanted device.

The ASR is a microchip designed to stimulate damaged retinal cells, allowing them to send visual signals again to the brain. As well as being a possible treatment option for retinitis pigmentosa, the manufacturers believe it could also be used to help treat age-related macular degeneration.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.